Psychotic Disorder Clinical Trial
Official title:
The Effects of Progressive Muscle Relaxation Therapy in Patients With Schizophrenia: Randomized Controlled Trials
This study applied a randomized parallel case-controlled design. The study purpose was to evaluate the effects of progressive muscle relaxation on anxiety, psychiatric symptoms and quality of life among patients with chronic schizophrenia compared with an active control.
Background: Anti-psychotic drugs are limited in their ability to improve psychiatric
symptoms, quality of life, and anxiety status in patients with chronic schizophrenia.
Progressive Muscle Relaxation (PMR) can potentially reduce anxiety status and improve
subjective welling in acute patients. It is an ideal rehabilitation intervention for patients
with chronic schizophrenia. However, no study has investigated the effects of PMR on outcomes
among patients with chronic schizophrenia.
Design: This study applied a randomized parallel case-controlled design.
Methods: Hospital-based randomized control trial in Taiwan. Eighty subjects with chronic
schizophrenia were recruited from a psychotic ward and randomized into PMR, or control
groups. Patients in the intervention group participated in progressive muscle relaxation for
12 weeks; while patients in the control group members received supportive treatment-as-usual
(TAU). All participants completed anxiety, psychotic syndromes and quality of life measures
at baseline, 3-month, and 3-month follow-up.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02306551 -
Well Being And Resilience: Mechanisms of Transmission of Health and Risk
|
||
| Active, not recruiting |
NCT00627029 -
Evaluation of Programs of Coordinated Care and Disease Management
|
N/A | |
| Terminated |
NCT00049738 -
Screening for Childhood-Onset Psychotic Disorders
|
N/A | |
| Withdrawn |
NCT01724372 -
The Role of Antidepressants or Antipsychotics in Preventing Psychosis
|
N/A | |
| Completed |
NCT00716755 -
Minimizing Doses of Antipsychotic Medication in Older Patients With Schizophrenia.
|
N/A | |
| Completed |
NCT00498550 -
Treatment of Schizophrenia and Comorbid Cannabis Use Disorder: Comparing Clozapine to Treatment-as-Usual
|
Phase 4 | |
| Terminated |
NCT04140773 -
The Effect of D-serine as add-on Therapy in Recent-onset Psychosis
|
N/A | |
| Completed |
NCT01473550 -
Mental Health Engagement Network (MHEN)
|
N/A | |
| Completed |
NCT01207219 -
Yoga and Aerobic Exercise in Psychosis
|
N/A | |
| Completed |
NCT00397033 -
Evaluation of Effectiveness and Safety of Paliperidone Extended Release in Patients With Schizoaffective Disorder.
|
Phase 3 | |
| Recruiting |
NCT04945278 -
Study of Self-Recognition and Self/Other Distinction Disorders in Patients With Psychological Vulnerability
|
N/A | |
| Completed |
NCT03955250 -
Mobile After-Care Support App: Pilot RCT
|
N/A | |
| Completed |
NCT00287352 -
Study of Amantadine for Weight Stabilization During Olanzapine Treatment
|
Phase 1 | |
| Completed |
NCT00005658 -
Glycine to Treat Psychotic Disorders in Children
|
Phase 2 | |
| Terminated |
NCT00169026 -
Alcoholism and Schizophrenia: Effects of Clozapine
|
Phase 4 | |
| Completed |
NCT00001482 -
New Drugs in the Treatment of Mood Disorders
|
Phase 2 | |
| Terminated |
NCT03671005 -
Mindfulness-based Group Therapy for Inpatients With Schizophrenia Spectrum Disorders
|
N/A | |
| Completed |
NCT00156715 -
Efficacy of Quetiapine in the Treatment of Patients With Schizophrenia and a Comorbid Substance Use Disorder
|
Phase 4 | |
| Completed |
NCT00095524 -
Effects of Aripiprazole in Overweight Patients Treated With Olanzapine for Schizophrenia or Schizoaffective Disorder
|
Phase 3 | |
| Completed |
NCT00001656 -
Comparison of Clozapine vs Olanzapine in Childhood-Onset Psychotic Disorders
|
Phase 4 |